J&J Medical Connect
TALVEY®

(talquetamab-tgvs)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TALVEY® (talquetamab-tgvs)
Medical Information

TALVEY - Use With Vaccines

Last Updated: 06/04/2026

SUMMARY

  • Immune response to vaccines may be reduced when taking TALVEY.1 
  • The safety of immunization with live viral vaccines during or following TALVEY treatment has not been studied.1
  • Vaccination with live virus vaccines is not recommended for at least 4 weeks prior to the start of treatment, during treatment, and at least 4 weeks after treatment.1

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 02 June 2026.

 

References

Show
1 Data on File. Talquetamab. CCDS. Janssen Research & Development, LLC. EDMS-RIM-620984; version 006; 2026.  

Would you like to clear and leave your conversation? Message history will be lost.